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Background/Aims: The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and 
metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and its 
prognostic implications in non-small-cell lung cancer (NSCLC) are still controversial.
Methods: Seventy-one paraffin-embedded tissue sections from stage I NSCLC patients were stained using a 
mouse monoclonal antibody against human IGF-1R.
Results: The intensity and frequency of IGF-1R expression on the membrane and cytoplasm of cancer cells was 
evaluated and scored using a semiquantitative system. IGF-1R expression was detected in nine of 71 (12.7%) cases. 
No significant relationship was found between clinical/histopathological parameters and IGF-1R expression. None of the 
patients whose tumor expressed IGF-1R had experienced distant metastasis or cancer-related death, although the 
difference did not reach statistical significance.
Conclusions: We conclude that IGF-1R expression may not be a major prognostic factor for stage I NSCLC.
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INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts for 
approximately 75～80% of all lung cancers and is the leading 
cause of cancer-related deaths worldwide1). However, 20% of 
stage I and 30% of stage II NSCLC patients who are treated 
with curative intent experience recurrence of their cancer, which 
is often incurable at the time of discovery. This statistic indicates 
the urgent need to elucidate the carcinogenesis of lung cancer 
and to devise new approaches for its prevention and treatment, 
such as chemoprevention.
The insulin-like growth factor (IGF) system plays a critical 
role in the growth and development of many tissues and 
regulates overall growth, particularly prenatal growth. It has also 
been implicated in various pathophysiological conditions and is 
thought to play a prominent role in tumorigenesis. The insulin- 
like growth factor-1 receptor (IGF-1R) is a glycosylated 
heterotetramer composed of two extracellular α- and β
-subunits that have intrinsic tyrosine kinase activity, and it 
shares 70% homology with the insulin receptor. It is encoded by 
the IGF-1R gene located on chromosome 15q262, 3). IGF-1R 
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mainly mediates the effect of IGFs, which are potent mitogens 
that regulate cell proliferation, differentiation, and protection from 
apoptosis4). Clinical and epidemiological data suggest that the 
serum levels of IGF-1 and IGF-binding proteins (IGFBPs) are 
related to the risk of solid tumors, such as breast, prostate, 
endometrial, ovarian, and colon cancer5). In breast cancer, 
IGF-1R expression and activation have been linked to disease 
progression, increased resistance to radiotherapy, and a poor 
prognosis6, 7). The expression of a dominant-negative truncated 
IGF-1R in colon cancer cells reduced the expression of 
vascular endothelial growth factor, impaired tumor progression 
in nude mice, and increased tumor cell apoptosis8). More 
focused studies of IGF-1R expression in the breast and 
prostate that used immunohistochemistry or matched cell lines 
corresponding to normal and tumor tissue revealed that normal 
epithelium and early-stage tumors both express abundant 
IGF-1R and that its expression is reduced significantly in 
advanced metastatic cancer9-13).
Although several commercial anti-IGF-1R antibodies are 
available, no scoring system for IGF-1R expression in 
formalin-fixed, paraffin-embedded tissue has been established. 
Here, we report the prognostic implications of IGF-1R 
expression as determined immunohistochemically using archived 
materials of stage I NSCLC. We evaluated its expression in 
cancer cell membranes and the cytoplasm and correlated its 
expression with various clinicopathological parameters.
MATERIAL AND METHODS
Study population and samples
We examined 71 tissue specimens from stage I NSCLC 
patients who had undergone curative surgical removal of 
primary lesions between 1995 and 1998 at Yonsei Medical 
Center. The pathological evaluation established the histological 
classification and stage in all patients. None of the patients had 
either radiotherapy or chemotherapy before or after surgery until 
the disease recurred. All clinical and pathological information 
and follow-up data were obtained from reports from our registry 
service. The study was reviewed and approved by the 
institution’s Surveillance Committee to allow us to obtain 
pertinent information from the patients’ files.
Immunohistochemical staining for IGF-1R
Paraffin-embedded, 4-µm-thick tissue sections were stained 
with mouse monoclonal antibody against human IGF-1R 
(BioSource International, Camarillo, CA, USA). The sections 
were deparaffinized in a xylene bath, rehydrated using a graded 
alcohol series, and retrieved in 10 mM sodium citrate buffer via 
microwave heating for 15 min at 95℃. The sections were then 
treated with 0.3% hydrogen peroxidase for 10 min to block 
endogenous peroxidase activity. Subsequently, the sections 
were incubated with the primary anti-IGF-1R antibody (1:50) for 
30 min at room temperature and processed using standard 
avidin-biotin immunohistochemical techniques according to the 
manufacturer’s recommendations (Vector Laboratories, Burlin-
game, CA, USA). Diaminobenzidine (DAB) was used as a chro-
mogen, and commercial hematoxylin was used for counter-
staining. Each time, placenta and breast cancer tissues were 
stained to serve as positive controls. Adjacent normal-appearing 
bronchial epithelium within each tissue section served as an 
internal reference. The intensity of IGF-1R immunostaining of 
the membrane and cytoplasm of the invasive cancer 
components was evaluated. Cell membrane and cytoplasm 
staining were scored on a scale of 0, 1+, 2+, and 3+, where 
scores of 1+ and above were classified as positive. All slides 
were evaluated and scored independently by two pathologists 
who were blind to the subjects’ clinical information.
Statistical analysis
In the univariate analysis, independent sample t-tests and 
Fisher’s exact tests were used for continuous and categorical 
variables, respectively. The Kaplan-Meier estimator was used to 
compute survival probability as a function of time. The log-rank 
test was used to compare survival time between groups. All 




The NSCLC cases included 51 (71.8%) males and 20 (28.2%) 
females with a median age of 61.8 (31-83) years, which is 
similar to the distribution in the large database of patients with 
stage I NSCLC from our institution (data not shown). Thirty-five 
(49.3%) patients were diagnosed with adenocarcinoma, 33 
(46.5%) with squamous cell carcinoma, and three (4.2%) with 
other histological subtypes. Fifty-eight (81.7%) patients had a 
history of smoking. The general clinical characteristics of the 
patients are shown in Table 1.
IGF-1R immunohistochemistry
IGF-1R expression was granular, heterogeneous, and 
discrete, i.e., mainly localized to the cytoplasm of NSCLC cells 
(Figure 1A and B). Some bronchioloalveolar carcinoma tissue 
showed distinct cytoplasmic IGF-1R expression (Fig. 1C). 
However, the number of NSCLC tissues expressing IGF-1R 
was small. There were 62 (87.3%), seven (9.9%), two (2.8%), 
and zero (0.0%) NSCLC cases with IGF-1R staining scores of 
0, 1+, 2+, and 3+, respectively. Cases with scores more than 1+ 
were defined as positive and were used for the subsequent 































































Total evaluated 71 12.7 87.3
*Bronchioloalveolar carcinoma 
Table 1. Analysis of the patients with stage I NSCLC according to the expression status of IGF-1R
statistical analysis. In the normal-appearing adjacent lung 
tissues, the cytoplasm of bronchial/bronchiolar epithelium 
showed uniform, constant IGF-1R expression. The immunohis-
tochemical staining of IGF-1R in breast cancer and placenta 
tissues was also stable and reproducible (data not shown).
Correlation of IGF-1R expression with the clinico-
pathological parameters
IGF-1R expression was positive in nine (12.7%) cases and 
negative in 62 (87.3%). IGF-1R expression was not associated 
with the clinical or pathological characteristics tested in this 
study (Table 1). The overall survival curves did not differ 
significantly between the group of patients with tumors 
expressing IGF-1R and those with negative IGF-1R expression 
(Figure 2). None of the patients with positive IGF-1R expression 
experienced distant metastasis or cancer-related death, 
although the difference did not reach significance (Table 1).
DISCUSSION
IGFs are potent mitogens in several types of cancer, 
including NSCLC and small-cell lung cancer15, 16). Furthermore, 
IGF-1R can upregulate several aspects of the malignant 
phenotype and metastasis in vitro17). In breast cancer, IGF-1R 
expression and activation have been linked to disease 
progression, increased resistance to radiotherapy, and a poor 
prognosis18, 19). For lung cancer, no data are available on 
IGF-1R expression, so we focused on the expression of 
IGF-1R in patients with stage I NSCLC and its significance to 
the clinical outcome. We tested the prognostic significance of 
IGF-1R expression in formalin-fixed, paraffin-embedded tissues.
We found that IGF-1R expression was downregulated in a 
significant fraction of patients with stage I NSCLC. Overall, nine 
of 71 tumors expressed IGF-1R, and its expression was 
localized to the membrane and cytoplasm, rather than the 
nucleus of NSCLC cells. Our data indicate that IGF-1R 
expression is not a prognostic factor in patients with stage I 
NSCLC. None of the patients expressing IGF-1R experienced 
distant metastasis or cancer-related death, although the 
difference was not significant. Our study did not show a better 
survival with IGF-1R expression. Other studies have shown that 
IGF-1R expression was significantly associated with a better 
survival in breast cancer and highly malignant soft tissue 
sarcoma20, 21), although other studies found the opposite22, 23). 
Early studies showed that functionality of the IGF-1R was a 
prerequisite for neoplastic transformation and for survival of the 
transformed cell in vitro and in vivo24). More recent evidence has 
pointed to putative roles for IGF-1R in cell adhesion and cancer 
cell dedifferentiation25). The significant association with survival 
observed in this study is of particular relevance, and should be 
confirmed in additional cohorts of patients.
In summary, in a homologous population of 71 patients with 
stage I NSCLC, we showed that IGF-1R expression is neither 
frequent nor a prognostic factor in stage I NSCLC. More 
comprehensive studies of the mechanism of IGF-1R expression 
in NSCLC are necessary to define the role of IGF-1R in lung 
carcinogenesis.
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Figure 1. Immunohistochemical analysis of IGF-1R expression in stage I NSCLC tissues. A. Poorly differentiated adenocarcinoma with 2+ 
IGF-1R expression (×400). B. Squamous cell carcinoma with 1+ IGF-1R expression (×200). C. Bronchioloalveolar carcinoma with 2+ 
IGF-1R expression (×200). D. Another bronchioloalveolar carcinoma that did not express IGF-1R (×200).
Figure 2. Survival curve for patients with stage I NSCLC stratified 
by IGF-1R expression. There was no significant difference between 
the curves for patients with and without IGF-1R expression.
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